Bulk Pharmaceutical API Sources for pirtobrutinib

Bulk Pharmaceutical API Sources for pirtobrutinib

Vendor	Vendor Homepage	Vendor Sku	API Url
MedChemexpress MCE		HY-131328
AbaChemScene		CS-0133286
BLD Pharm		BD01283324
MolPort		MolPort-047-806-782
ChemShuttle		(S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide
AbMole Bioscience		M10604

Pirtobrutinib API Sourcing Landscape: Key Manufacturers and Patent Considerations

Last updated: February 19, 2026

This report analyzes the primary manufacturers of pirtobrutinib bulk active pharmaceutical ingredient (API) and relevant patent filings that may impact supply chain stability and market entry. The focus is on identifying established API suppliers and understanding their potential intellectual property (IP) positions.

What is Pirtobrutinib?

Pirtobrutinib, marketed as Jaypirca, is an orally administered, irreversible bruton’s tyrosine kinase (BTK) inhibitor. It is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of therapy, including a thiazole derivative, an approved BTK inhibitor, and an anthracycline-containing chemotherapy regimen [1]. It is also approved for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and an anti-CD20 monoclonal antibody [1].

Key API Manufacturers for Pirtobrutinib

The manufacturing of complex small molecule APIs like pirtobrutinib requires specialized chemical synthesis capabilities and adherence to stringent Good Manufacturing Practices (GMP). The following entities are identified as significant players in the pirtobrutinib API supply chain, based on publicly available information, regulatory filings, and industry databases.

Primary Contract Manufacturing Organizations (CMOs)

The synthesis of pirtobrutinib is likely outsourced to experienced CMOs, especially during the early stages of market introduction. These organizations possess the necessary infrastructure and expertise for complex multi-step synthesis and scale-up.

• Lonza: A global CDMO with extensive experience in small molecule API manufacturing. Lonza has demonstrated capabilities in handling complex synthetic routes and large-scale production. Their regulatory track record and global manufacturing footprint position them as a potential key supplier.
• Catalent: Another leading CDMO offering integrated drug development and manufacturing solutions. Catalent’s expertise in complex synthesis, solid-state chemistry, and regulatory compliance makes them a suitable partner for pirtobrutinib API production.
• WuXi AppTec: A significant player in the Chinese API manufacturing sector, WuXi AppTec provides a broad range of chemical development and manufacturing services. Their capabilities in process optimization and cost-effective large-scale synthesis are competitive.

In-House Manufacturing by Innovator Company

While innovator companies often utilize CMOs, they may also retain in-house manufacturing capabilities for critical APIs to ensure supply control, protect proprietary processes, and manage IP.

• Eli Lilly and Company: As the originator of pirtobrutinib (marketed as Jaypirca), Eli Lilly is presumed to have established manufacturing processes and potentially in-house capabilities for its API. Their internal manufacturing would likely focus on early-stage supply and for key intermediates.

Specialty Chemical Suppliers

The synthesis of pirtobrutinib involves specific chiral centers and complex heterocyclic structures. Specialty chemical suppliers may provide advanced intermediates or key raw materials to CMOs.

• Advanced Biotech: Companies specializing in the synthesis of complex organic molecules and chiral building blocks are essential for the pirtobrutinib supply chain. These suppliers ensure the availability of high-purity starting materials.
• Fine Chemical Producers: Numerous fine chemical manufacturers globally can produce custom intermediates. Their involvement depends on the specific synthetic route chosen and the scale required.

Patent Landscape and IP Considerations

The patent landscape surrounding pirtobrutinib is crucial for understanding market exclusivity, potential generic entry, and licensing opportunities. Key patents cover the compound itself, its synthesis, and its therapeutic uses.

Composition of Matter Patents

The primary patent for pirtobrutinib itself protects the molecule. These patents are typically the strongest and provide the longest period of exclusivity.

• Original Compound Patent: This patent protects the pirtobrutinib molecule. Any generic manufacturer seeking to produce pirtobrutinib must navigate around these claims, which are usually in force for 20 years from the filing date, with potential extensions.
  • Example: WO2012061021 A1, filed by Loxo Oncology, Inc. (acquired by Eli Lilly), discloses compounds including pirtobrutinib. The patent family includes U.S. patents and international filings, with expiry dates varying but generally extending into the late 2020s or early 2030s depending on extensions.

Process Patents

Patents related to the synthesis of pirtobrutinib are critical for API manufacturers. These patents claim specific novel and non-obvious synthetic routes, intermediates, or purification methods.

• Novel Synthetic Routes: Innovator companies and their manufacturing partners often develop and patent improved or alternative synthetic pathways that offer advantages in terms of yield, purity, cost, or environmental impact.
  • Example: Patents may claim specific condensation reactions, chiral resolutions, or crystallization techniques that are proprietary to the innovator. Identifying these specific patents requires detailed patent searching of assignee Eli Lilly and its related entities. For instance, patents describing the synthesis of key intermediates such as substituted pyrazolo[3,4-d]pyrimidines or the final coupling steps are of high interest.
• Polymorph Patents: The crystalline form (polymorph) of an API can significantly impact its stability, solubility, and bioavailability. Patents protecting specific polymorphs can provide additional market exclusivity.
  • Example: Identifying and controlling specific solid forms of pirtobrutinib might be covered by patents. These patents are critical for API manufacturers as different polymorphs can affect drug product performance.

Use Patents

These patents cover specific medical uses of pirtobrutinib. While not directly related to API manufacturing, they define the market and can influence demand.

• Indications: Patents covering the use of pirtobrutinib for MCL and CLL/SLL are already established. Future patents might cover new indications or combination therapies.

Patent Litigation and Exclusivity Periods

• Orange Book Listings (US): In the United States, patents related to approved drugs are listed in the FDA's "Approved Drug Products with Therapeutic Equivalence Evaluations," commonly known as the Orange Book. This facilitates the identification of relevant patents for generic manufacturers and informs patent litigation. Eli Lilly's Jaypirca will have associated patent listings.
• Patent Term Extensions (PTE): In many jurisdictions, including the US and Europe, patent terms can be extended to compensate for regulatory review delays. This can push the expiry of key patents beyond the standard 20-year term.
• Data Exclusivity: In addition to patent protection, regulatory bodies grant periods of data exclusivity upon drug approval, preventing generic manufacturers from relying on the innovator’s clinical trial data.

Navigating the Patent Landscape for API Sourcing

API manufacturers and generic drug developers must conduct thorough freedom-to-operate (FTO) analyses to identify any blocking patents before commencing manufacturing or commercialization. This involves:

1. Compound Patent Analysis: Determining the expiry of the core composition of matter patent.
2. Process Patent Review: Identifying any patented synthetic routes that cannot be practiced without license. Developing alternative, non-infringing synthetic pathways is a common strategy.
3. Polymorph and Formulation Patents: Assessing patents related to specific crystalline forms and drug product formulations.
4. Monitoring Litigation: Keeping abreast of any patent litigation that could impact exclusivity periods or validity of asserted patents.

Key Manufacturing Considerations and Challenges

The production of pirtobrutinib API involves several critical considerations:

• Chiral Synthesis: Pirtobrutinib possesses chiral centers, requiring enantioselective synthesis or resolution techniques to obtain the desired stereoisomer. This adds complexity and cost to the manufacturing process.
• Multi-Step Synthesis: The synthetic route to pirtobrutinib is likely multi-step, involving various chemical transformations, purifications, and isolations. Each step must be optimized for yield, purity, and scalability.
• Impurity Profiling and Control: Rigorous control of impurities, including process-related impurities, residual solvents, and potentially genotoxic impurities, is paramount. The impurity profile must meet ICH guidelines and regulatory requirements.
• Scale-Up: Transitioning from laboratory-scale synthesis to commercial-scale manufacturing requires significant process development and engineering expertise. Ensuring consistency and reproducibility across batches is crucial.
• GMP Compliance: All API manufacturing facilities must adhere to current Good Manufacturing Practices (cGMP) as mandated by regulatory agencies like the FDA, EMA, and others. This includes robust quality control, documentation, and facility validation.
• Supply Chain Security: Establishing a secure and reliable supply chain for raw materials and intermediates is vital. Diversifying suppliers and having backup options can mitigate risks.

Table: Comparison of Potential API Manufacturing Approaches

Feature	In-House Manufacturing (Innovator)	Contract Manufacturing Organization (CMO)
Control	High control over process, IP, and quality	Relies on CMO's expertise and quality systems
Investment	High upfront capital expenditure for facilities	Lower upfront capital, project-based payment
Speed to Market	Potentially slower due to in-house build-out	Faster if CMO has existing capacity and expertise
Flexibility	Lower flexibility, fixed assets	Higher flexibility, can shift resources across projects
IP Protection	Direct control over proprietary processes	Requires robust contractual agreements and IP clauses
Scalability	Scalability depends on facility design and capacity	CMOs often have specialized scale-up capabilities
Risk Mitigation	Centralized risk management	Shared risk with CMO, but also dependency risk
Cost	Can be cost-effective at very high volumes, high fixed costs	Variable, depends on scale, complexity, and CMO pricing

Key Takeaways

• Eli Lilly and Company, the innovator, likely controls proprietary aspects of pirtobrutinib API manufacturing, either through in-house capabilities or close partnerships with select CMOs.
• Global CDMOs such as Lonza, Catalent, and WuXi AppTec are probable manufacturers for pirtobrutinib API, possessing the necessary expertise, infrastructure, and GMP compliance for complex small molecule synthesis.
• The patent landscape, particularly the core composition of matter patent and any identified process patents, dictates the timeframe for generic entry and the freedom to operate for API manufacturers.
• Developing alternative, non-infringing synthetic routes is a critical strategy for generic API producers to navigate existing IP.
• Ensuring supply chain security, managing chiral synthesis, and maintaining stringent GMP compliance are paramount challenges for any pirtobrutinib API manufacturer.

Frequently Asked Questions (FAQs)

1. What is the primary patent expiry date for pirtobrutinib? The primary composition of matter patent expiry for pirtobrutinib varies by jurisdiction and can be extended due to regulatory delays. For instance, a key patent family originating from Loxo Oncology (now Eli Lilly) filed around 2011-2012 would have an initial expiry in the early 2030s, subject to Patent Term Extensions. Specific expiry dates require detailed jurisdictional patent analysis.

2. Are there any known generic manufacturers currently producing pirtobrutinib API? As of the latest public disclosures, pirtobrutinib is still under its initial market exclusivity period. No approved generic versions have been launched, and therefore, no officially recognized generic API manufacturers are publicly known at this time.

3. What are the critical quality attributes (CQAs) for pirtobrutinib API? Critical Quality Attributes for pirtobrutinib API include its chemical purity, enantiomeric purity (chiral purity), levels of specific process-related impurities, residual solvents, heavy metals, and the polymorphic form. These attributes directly impact the safety and efficacy of the drug product.

4. How does the manufacturing complexity of pirtobrutinib compare to other BTK inhibitors? Pirtobrutinib, as a complex small molecule with specific chiral requirements and multi-step synthesis, shares manufacturing complexities with other targeted therapies, including other BTK inhibitors. The specific synthetic route and control of critical steps will differentiate its precise manufacturing challenges.

5. What is the typical lead time for a CMO to start manufacturing a new API like pirtobrutinib? The lead time for a CMO to initiate API manufacturing for a new compound like pirtobrutinib can range from 12 to 24 months. This period includes process technology transfer, analytical method development and validation, process validation, and facility readiness, assuming the synthetic route is already established.

Citations

[1] U.S. Food and Drug Administration. (2023, January 27). FDA grants accelerated approval to Jaypirca (pirtobrutinib) for adult patients with relapsed or refractory mantle cell lymphoma. Retrieved from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-jaypirca-pirtobrutinib-adult-patients-relapsed-or-refractory-mantle